Quick Answer
Valion Bio, Inc. reported Diluted EPS of $19.68 per share (loss) for fiscal year 2024.
Valion Bio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$19.68 | +88.9% |
| 2023 | -$176.80 | -69.5% |
| 2022 | -$104.32 | -4193.0% |
| 2021 | -$2.43 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$2.19 | +59.2% | +13.1% |
| March 31, 2025 | -$2.52 | +85.3% | -995.7% |
| September 30, 2024 | -$0.23 | +84.5% | +95.7% |
| June 30, 2024 | -$5.37 | +25.0% | +68.7% |
| March 31, 2024 | -$17.15 | -63.0% | -1058.8% |
| September 30, 2023 | -$1.48 | +94.5% | +79.3% |
| June 30, 2023 | -$7.16 | -2137.5% | +31.9% |
| March 31, 2023 | -$10.52 | -4473.9% | +61.0% |
- Valion Bio, Inc. showed an increase of +88.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, Valion Bio, Inc.’s diluted eps has declined by 709.9% (from $2.43 per share (loss) to $19.68 per share (loss)).
- The most recent figure is from Valion Bio, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 21, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: